Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Treasury Shares: 2011-2017

Historic Treasury Shares for Gyre Therapeutics (GYRE) over the last 7 years, with Dec 2017 value amounting to $821,741.

  • Gyre Therapeutics' Treasury Shares rose 19.01% to $1.6 million in Q3 2019 from the same period last year, while for Sep 2019 it was $1.6 million, marking a year-over-year increase of 19.01%. This contributed to the annual value of $821,741 for FY2017, which is 482.84% up from last year.
  • Gyre Therapeutics' Treasury Shares amounted to $821,741 in FY2017, which was up 482.84% from $140,990 recorded in FY2016.
  • In the past 5 years, Gyre Therapeutics' Treasury Shares ranged from a high of $1.4 million in FY2013 and a low of $103,129 during FY2015.
  • Moreover, its 3-year median value for Treasury Shares was $140,990 (2016), whereas its average is $355,287.
  • As far as peak fluctuations go, Gyre Therapeutics' Treasury Shares plummeted by 79.89% in 2015, and later surged by 482.84% in 2017.
  • Over the past 5 years, Gyre Therapeutics' Treasury Shares (Yearly) stood at $1.4 million in 2013, then slumped by 62.24% to $512,700 in 2014, then plummeted by 79.89% to $103,129 in 2015, then surged by 36.71% to $140,990 in 2016, then soared by 482.84% to $821,741 in 2017.